Detection Test By Immunoassay With Direct Visual Observation For Severe Acute Respiratory Syndrome Coronavirus 2 (covid-19) in West Virginia
Estimated using RAND 2024 commercial-to-Medicare ratios. Actual prices vary by insurer, plan, and facility.
Top Providers in West Virginia
| Provider | Medicare | Services |
|---|---|---|
| Fink, Rodney D.O. | $24.50 | 640 |
West Virginia Pricing in Context
In West Virginia, CPT code 87811 (Detection Test By Immunoassay With Direct Visual Observation For Severe Acute Respiratory Syndrome Coronavirus 2 (covid-19)) carries an average Medicare payment of $38.06 — 5% below the national benchmark of $40.14. 193 providers across the state submitted claims for this procedure in 2023, performing 5.0K total services. Individual payments in WV ranged from N/A at the low end to N/A at the high end, reflecting differences in provider setting (office vs. facility), modifiers, and the specific geographic locality code applied within the state.
The average billed charge in West Virginia is $72.01, which is the figure uninsured patients would most likely encounter before any negotiation or charity discount. Medicare, by statute, only reimburses the allowed amount — the balance between billed and paid is written off under provider participation agreements. Insured patients generally pay a negotiated rate that falls between these two figures; the exact amount depends on plan design, deductible status, and in-network participation. Because West Virginia sits below the national Medicare average, commercial rates in the state may also run lower than the US median.
Using RAND 2024 commercial-to-Medicare ratios for Immunology procedures, the estimated commercial insurance price in West Virginia lands near $81.83, with self-pay cash prices typically around $48.35. Before scheduling, patients can request a Good Faith Estimate under the No Surprises Act, compare cash rates from hospital Machine-Readable Files, and confirm whether the provider is in-network with their specific plan. This page presents CMS reference data for informational use; it does not constitute medical or financial advice.
Frequently Asked Questions
How much does Detection Test By Immunoassay With Direct Visual Observation For Severe Acute Respiratory Syndrome Coronavirus 2 (covid-19) cost in West Virginia?
The average Medicare payment for Detection Test By Immunoassay With Direct Visual Observation For Severe Acute Respiratory Syndrome Coronavirus 2 (covid-19) in West Virginia is $38.06, which is 5% below the national average of $40.14. Providers in WV typically bill $72.01 for this procedure.
What does Detection Test By Immunoassay With Direct Visual Observation For Severe Acute Respiratory Syndrome Coronavirus 2 (covid-19) cost with insurance in West Virginia?
With commercial insurance in West Virginia, Detection Test By Immunoassay With Direct Visual Observation For Severe Acute Respiratory Syndrome Coronavirus 2 (covid-19) costs an estimated $81.83. Without insurance, the estimated cash price is $48.35. These estimates are based on RAND 2024 commercial-to-Medicare ratios and vary by insurer, plan, and facility.
How many providers perform Detection Test By Immunoassay With Direct Visual Observation For Severe Acute Respiratory Syndrome Coronavirus 2 (covid-19) in West Virginia?
193 providers in West Virginia billed Medicare for Detection Test By Immunoassay With Direct Visual Observation For Severe Acute Respiratory Syndrome Coronavirus 2 (covid-19) in 2023, performing 5.0K total services. Medicare payments ranged from N/A to N/A depending on the provider.
Is Detection Test By Immunoassay With Direct Visual Observation For Severe Acute Respiratory Syndrome Coronavirus 2 (covid-19) cheaper in West Virginia than the national average?
Yes — Detection Test By Immunoassay With Direct Visual Observation For Severe Acute Respiratory Syndrome Coronavirus 2 (covid-19) costs 5% below the national average in West Virginia. The state average Medicare payment is $38.06 compared to $40.14 nationally. Factors like local cost of living, provider competition, and regional Medicare fee schedules all influence state-level pricing.
Related Guides
Related Data Sources
Data from CMS Medicare Physician & Other Practitioners (2023).
Read our methodology — how this data is sourced, computed, and verified.